Amgen Inc. (NASDAQ:AMGN) Shares Sold by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 2.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,887 shares of the medical research company’s stock after selling 67 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Amgen were worth $930,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Capital Asset Advisory Services LLC grew its position in Amgen by 18.7% in the first quarter. Capital Asset Advisory Services LLC now owns 1,759 shares of the medical research company’s stock valued at $475,000 after acquiring an additional 277 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in Amgen by 37.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 11,642 shares of the medical research company’s stock valued at $3,310,000 after purchasing an additional 3,168 shares in the last quarter. Griffin Asset Management Inc. increased its stake in Amgen by 12.3% during the 1st quarter. Griffin Asset Management Inc. now owns 911 shares of the medical research company’s stock worth $259,000 after buying an additional 100 shares during the period. Symphony Financial Ltd. Co. lifted its holdings in Amgen by 3.5% in the 1st quarter. Symphony Financial Ltd. Co. now owns 8,260 shares of the medical research company’s stock worth $2,349,000 after buying an additional 277 shares in the last quarter. Finally, Brown Miller Wealth Management LLC boosted its position in Amgen by 1.1% in the 1st quarter. Brown Miller Wealth Management LLC now owns 6,703 shares of the medical research company’s stock valued at $1,905,000 after buying an additional 71 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AMGN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. Sanford C. Bernstein started coverage on Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price on the stock. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and upped their price target for the company from $320.00 to $333.00 in a report on Monday, October 14th. Finally, Oppenheimer reissued an “outperform” rating and set a $380.00 price objective on shares of Amgen in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $316.98 on Friday. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The firm has a market capitalization of $170.04 billion, a PE ratio of 45.28, a P/E/G ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The business’s fifty day moving average price is $325.58 and its two-hundred day moving average price is $313.14.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter last year, the company posted $5.00 EPS. Amgen’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, research analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.84%. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.